Transgenic Models to Understand Hypoxia-Inducible Factor Function

Methods in Enzymology

Volumn 435, Issue , 2007, Pages 87-105

  Doedens, Andrew ^a   Johnson, Randall S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ASTROCYTOMA; BONE MARROW CELL; BREAST CANCER; CARCINOGENESIS; CARDIOVASCULAR SYSTEM; CARTILAGE CELL; CELL LINEAGE; COLON; GENE DELETION; HEMATOPOIESIS; HETEROZYGOTE; HYPOXIA; LIVER; LYMPHOCYTE; MAMMARY GLAND; MOTONEURON; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; TRANSGENIC MOUSE; VON HIPPEL LINDAU DISEASE; XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; CELL HYPOXIA; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MOUSE; NEOPLASM;

MAMMALIA; MURINAE;

ANIMALS; CELL HYPOXIA; GROWTH AND DEVELOPMENT; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 39749142651     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)35005-2     Document Type: Review

References (82)

1. Acker T., Diez-Juan A., Aragones J., Tjwa M., Brusselmans K., Moons L., Fukumura D., Moreno-Murciano M.P., Herbert J.M., Burger A., Riedel J., Evert G., et al. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8 (2005) 131-141
2. Beck I., Ramirez S., Weinmann R., and Caro J. Enhancer element at the 3′-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J. Biol. Chem. 266 (1991) 15563-15566
3. Biju M.P., Neumann A.K., Bensinger S.J., Johnson R.S., Turka L.A., and Haase V.H. Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol. Cell. Biol. 24 (2004) 9038-9047
4. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., and Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003) 133-146
5. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
6. Brusselmans K., Compernolle V., Tjwa M., Wiesener M.S., Maxwell P.H., Collen D., and Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J. Clin. Invest. 111 (2003) 1519-1527
7. Bunger M.K., Wilsbacher L.D., Moran S.M., Clendenin C., Radcliffe L.A., Hogenesch J.B., Simon M.C., Takahashi J.S., and Bradfield C.A. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103 (2000) 1009-1017
8. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
9. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
10. Compernolle V., Brusselmans K., Franco D., Moorman A., Dewerchin M., Collen D., and Carmeliet P. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1α. Cardiovasc. Res. 60 (2003) 569-579
11. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., Nemery B., Dewerchin M., et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8 (2002) 702-710
12. Cowden K.D., and Simon M.C. The bHLH/PAS factor MOP3 does not participate in hypoxia responses. Biochem. Biophys. Res. Commun. 290 (2002) 1228-1236
13. Cramer T., and Johnson R.S. A novel role for the hypoxia inducible transcription factor HIF-1α: Critical regulation of inflammatory cell function. Cell Cycle 2 (2003) 192-193
14. Cramer T., Yamanishi Y., Clausen B.E., Förster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., Firestein G.S., Gerber H.P., et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
15. Detwiller K.Y., Fernando N.T., Segal N.H., Ryeom S.W., D'Amore P.A., and Yoon S.S. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res. 65 (2005) 5881-5889
16. Elson D.A., Thurston G., Huang L.E., Ginzinger D.G., McDonald D.M., Johnson R.S., and Arbeit J.M. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev. 15 (2001) 2520-2532
17. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 94 (1997) 4273-4278
18. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
19. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
20. Flamme I., Frohlich T., von Reutern M., Kappel A., Damert A., and Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 α and developmentally expressed in blood vessels. Mech. Dev. 63 (1997) 51-60
21. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.A., Rangell L., Wright B.D., Radtke F., Aguet M., and Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 126 (1999) 1149-1159
22. Gnarra J.R., Ward J.M., Porter F.D., Wagner J.R., Devor D.E., Grinberg A., Emmert-Buck M.R., Westphal H., Klausner R.D., and Linehan W.M. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA 94 (1997) 9102-9107
23. Gruber M., Hu C.J., Johnson R.S., Brown E.J., Keith B., and Simon M.C. Acute postnatal ablation of Hif-2α results in anemia. Proc. Natl. Acad. Sci. USA 104 (2007) 2301-2306
24. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., and Bradfield C.A. Molecular characterization and chromosomal localization of a third α-class hypoxia inducible factor subunit, HIF3α. Gene Expr. 7 (1998) 205-213
25. Haase V.H., Glickman J.N., Socolovsky M., and Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA 98 (2001) 1583-1588
26. Helton R., Cui J., Scheel J.R., Ellison J.A., Ames C., Gibson C., Blouw B., Ouyang L., Dragatsis I., Zeitlin S., Johnson R.S., Lipson S.A., et al. Brain-specific knock-out of hypoxia-inducible factor-1α reduces rather than increases hypoxic-ischemic damage. J. Neurosci. 25 (2005) 4099-4107
27. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W., Elkins J.M., Oldham N.J., Bhattacharya S., Gleadle J.M., Ratcliffe P.J., Pugh C.W., et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277 (2002) 26351-26355
28. Hogenesch J.B., Gu Y.Z., Jain S., and Bradfield C.A. The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc. Natl. Acad. Sci. USA 95 (1998) 5474-5479
29. Huang Y., Hickey R.P., Yeh J.L., Liu D., Dadak A., Young L.H., Johnson R.S., and Giordano F.J. Cardiac myocyte-specific HIF-1α deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 18 (2004) 1138-1140
30. 2 sensing. Science 292 (2001) 464-468
31. 2 homeostasis by hypoxia-inducible factor 1 α. Genes Dev. 12 (1998) 149-162
32. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
33. Jensen R.L., Ragel B.T., Whang K., and Gillespie D. Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J. Neurooncol. 78 (2006) 233-247
34. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2 (2002) 673-682
35. Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13 (2007) 680s-684s
36. Karhausen J., Furuta G.T., Tomaszewski J.E., Johnson R.S., Colgan S.P., and Haase V.H. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 114 (2004) 1098-1106
37. Keith B., Adelman D.M., and Simon M.C. Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with. Arnt. Proc. Natl. Acad. Sci. USA 98 (2001) 6692-6697
38. Kim W.Y., Safran M., Buckley M.R., Ebert B.L., Glickman J., Bosenberg M., Regan M., and Kaelin Jr. W.G. Failure to prolyl hydroxylate hypoxia-inducible factor α phenocopies VHL inactivation in vivo. EMBO J. 25 (2006) 4650-4662
39. Kozak K.R., Abbott B., and Hankinson O. ARNT-deficient mice and placental differentiation. Dev. Biol. 191 (1997) 297-305
40. Larcher F., Murillas R., Bolontrade M., Conti C.J., and Jorcano J.L. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17 (1998) 303-311
41. Li L., Lin X., Staver M., Shoemaker A., Semizarov D., Fesik S.W., and Shen Y. Evaluating hypoxia-inducible factor-1α as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res. 65 (2005) 7249-7258
42. Liao D., Corle C., Seagroves T.N., and Johnson R.S. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67 (2007) 563-572
43. Lin E.Y., Jones J.G., Li P., Zhu L., Whitney K.D., Muller W.J., and Pollard J.W. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163 (2003) 2113-2126
44. -/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol. Cell Biol. 25 (2005) 4565-4578
45. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
46. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., and Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386 (1997) 403-407
47. Maltepe E., Keith B., Arsham A.M., Brorson J.R., and Simon M.C. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem. Biophys. Res. Commun. 273 (2000) 231-238
48. Mason S.D., Howlett R.A., Kim M.J., Olfert I.M., Hogan M.C., McNulty W., Hickey R.P., Wagner P.D., Kahn C.R., Giordano F.J., and Johnson R.S. Loss of skeletal muscle HIF-1α results in altered exercise endurance. PLoS Biol. 2 (2004) e288
49. Neumann A.K., Yang J., Biju M.P., Joseph S.K., Johnson R.S., Haase V.H., Freedman B.D., and Turka L.A. Hypoxia inducible factor 1 α regulates T cell receptor signal transduction. Proc. Natl. Acad. Sci. USA 102 (2005) 17071-17076
50. Ohh M., Yauch R.L., Lonergan K.M., Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., Gavin B.J., Kley N., Kaelin Jr. W.G., and Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1 (1998) 959-968
51. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28 (2001) 131-138
52. Orban P.C., Chui D., and Marth J.D. Tissue- and site-specific DNA recombination in transgenic mice. Proc. Natl. Acad. Sci. USA 89 (1992) 6861-6865
53. Park S.K., Haase V.H., and Johnson R.S. Von Hippel Lindau tumor suppressor regulates hepatic glucose metabolism by controlling expression of glucose transporter 2 and glucose 6-phosphatase. Int. J. Oncol. 30 (2007) 341-348
54. Peng J., Zhang L., Drysdale L., and Fong G.H. The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc. Natl. Acad. Sci. USA 97 (2000) 8386-8391
55. Peng Y.J., Yuan G., Ramakrishnan D., Sharma S.D., Bosch-Marce M., Kumar G.K., Semenza G.L., and Prabhakar N.R. Heterozygous HIF-1α deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J. Physiol. 577 (2006) 705-716
56. Peyssonnaux C., Datta V., Cramer T., Doedens A., Theodorakis E.A., Gallo R.L., Hurtado-Ziola N., Nizet V., and Johnson R.S. HIF-1α expression regulates the bactericidal capacity of phagocytes. J. Clin. Invest. 115 (2005) 1806-1815
57. Pugh C.W., Tan C.C., Jones R.W., and Ratcliffe P.J. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc. Natl. Acad. Sci. USA 88 (1991) 10553-10557
58. Rankin E.B., Tomaszewski J.E., and Haase V.H. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 66 (2006) 2576-2583
59. 2 transport. J. Clin. Invest. 96 (1995) 1916-1926
60. Ryan H.E., Lo J., and Johnson R.S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17 (1998) 3005-3015
61. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60 (2000) 4010-4015
62. Safran M., Kim W.Y., O'Connell F., Flippin L., Gunzler V., Horner J.W., Depinho R.A., and Kaelin Jr. W.G. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc. Natl. Acad. Sci. USA 103 (2006) 105-110
63. Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods 14 (1998) 381-392
64. Schipani E., Ryan H.E., Didrickson S., Kobayashi T., Knight M., and Johnson R.S. Hypoxia in cartilage: HIF-1α is essential for chondrocyte growth arrest and survival. Genes Dev. 15 (2001) 2865-2876
65. Scortegagna M., Morris M.A., Oktay Y., Bennett M., and Garcia J.A. The HIF family member EPAS1/HIF-2α is required for normal hematopoiesis in mice. Blood 102 (2003) 1634-1640
66. -/- mice. Nat. Genet. 35 (2003) 331-340
67. Scortegagna M., Ding K., Zhang Q., Oktay Y., Bennett M.J., Bennett M., Shelton J.M., Richardson J.A., Moe O., and Garcia J.A. HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105 (2005) 3133-3140
68. Seagroves T.N., Hadsell D., McManaman J., Palmer C., Liao D., McNulty W., Welm B., Wagner K.U., Neville M., and Johnson R.S. HIF1α is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development 130 (2003) 1713-1724
69. Semenza G.L. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 7 (2001) 345-350
70. Semenza G.L. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp. Physiol. 91 (2006) 803-806
71. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12 (1992) 5447-5454
72. Semenza G.L., Roth P.H., Fang H.M., and Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269 (1994) 23757-23763
73. Takeda K., Ho V.C., Takeda H., Duan L.J., Nagy A., and Fong G.H. Placental but not heart defects are associated with elevated hypoxia-inducible factor α levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell Biol. 26 (2006) 8336-8346
74. Tang N., Mack F., Haase V.H., Simon M.C., and Johnson R.S. pVHL function is essential for endothelial extracellular matrix deposition. Mol. Cell Biol. 26 (2006) 2519-2530
75. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., and Johnson R.S. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495
76. Tian H., McKnight S.L., and Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11 (1997) 72-82
77. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12 (1998) 3320-3324
78. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270 (1995) 1230-1237
79. 2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
80. Wiener C.M., Booth G., and Semenza G.L. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 225 (1996) 485-488
81. Yu A.Y., Shimoda L.A., Iyer N.V., Huso D.L., Sun X., McWilliams R., Beaty T., Sham J.S., Wiener C.M., Sylvester J.T., and Semenza G.L. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J. Clin. Invest. 103 (1999) 691-696
82. Zhang Q., Zhang Z.F., Rao J.Y., Sato J.D., Brown J., Messadi D.V., and Le A.D. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1α induced apoptosis in human tongue squamous cell carcinomas. Int. J. Cancer 111 (2004) 849-857